GENENTA SCIENCE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.3 USD | +3.77% |
|
+6.45% | -33.33% |
| 06/05 | Genenta Science S.p.A. Announces New Board Appointments | CI |
| 08/04 | Genenta Science S.P.A. Announces Resignation of Board Members | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 5.55Cr 6.03Cr 502.79Cr |
|---|---|---|---|---|---|
| Net income 2024 * | -1.8Cr -1.96Cr -163.02Cr | Net income 2025 * | -2.4Cr -2.61Cr -217.36Cr | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.61
x | P/E ratio 2025 * |
-3.41
x | Employees | 14 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.08% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.77% | ||
| 1 week | +6.45% | ||
| Current month | +7.14% | ||
| 1 month | -15.41% | ||
| 3 months | -25.34% | ||
| 6 months | -38.89% | ||
| Current year | -33.33% |
1 week
3.00
3.50
1 month
2.204.22
Current year
2.204.96
1 year
2.206.81
3 years
2.2013.13
5 years
2.2013.13
10 years
2.2013.13
| Managers | Title | Age | Since |
|---|---|---|---|
Bernhard Gentner
FOU | Founder | - | 24/14/24 |
Luigi Naldini
FOU | Founder | - | 24/14/24 |
| Chief Executive Officer | 50 | 24/14/24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 62 | 20/21/20 |
Roger Abravanel
BRD | Director/Board Member | 77 | 20/21/20 |
| Chief Executive Officer | 50 | 24/14/24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 3.3 | +3.77% | 1,686 |
| 16/24/16 | 3.18 | -0.63% | 1,341 |
| 15/24/15 | 3.2 | -0.62% | 3,556 |
| 14/24/14 | 3.22 | -8.15% | 2,070 |
| 13/24/13 | 3.506 | +13.09% | 1,082 |
Delayed Quote Nasdaq, May 18, 2024 at 02:00 am IST
More quotes
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.035
EUR
Average target price
21.36
EUR
Spread / Average Target
+603.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.33% | 6.04Cr | |
| +33.63% | 5.09TCr | |
| -0.09% | 4.21TCr | |
| +49.62% | 4.2TCr | |
| -4.96% | 2.92TCr | |
| +11.18% | 2.6TCr | |
| -21.95% | 1.89TCr | |
| +8.61% | 1.32TCr | |
| +24.73% | 1.22TCr | |
| +28.31% | 1.22TCr |
- Stock Market
- Equities
- GNTA Stock
